$53.0M
The oversubscribed round was co-led by IQ Capital and Molten Ventures to expand the company's immune profiling platform.
IB
IMU Biosciences
Mapping the human immune system through advanced blood analysis.
London, UK—Founded 2021
$64.5MTotal raised
A biotechnology company that maps the human immune system using single blood samples and artificial intelligence.
Categories
Founders
Adam Laing
President and Chief Scientific Officer
Adam serves as co-founder, president and chief scientific officer at IMU Biosciences, having previously held the role of chief executive officer at the same organisation. Before founding IMU Biosciences, he spent eight years as a research associate at King's College London.
LinkedIn
Tom Hayday
Chief Scientific Officer
Tom brings research experience from King's College London to his role as co-founder and chief research officer at IMU Biosciences.
LinkedIn
Mario Cantero
Chief Operating Officer
Mario serves as co-founder and chief operating officer at IMU Biosciences. His previous roles include chief operating officer at Werlabs and vice president of business intelligence at Jobandtalent.
LinkedInInvestors
- $53.0M
- £11.5M
Funding history
£11.5M
The financing round was led by Molten Ventures with backing from LifeX Ventures and private individuals.